Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Payables: 2016-2025

Historic Payables for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $112.3 million.

  • Tg Therapeutics' Payables rose 10.78% to $112.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $438.6 million, marking a year-over-year increase of 36.79%. This contributed to the annual value of $58.3 million for FY2024, which is 51.53% up from last year.
  • As of Q3 2025, Tg Therapeutics' Payables stood at $112.3 million, which was down 16.18% from $134.0 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Payables ranged from a high of $134.0 million in Q2 2025 and a low of $29.7 million during Q3 2022.
  • Moreover, its 3-year median value for Payables was $87.3 million (2024), whereas its average is $83.5 million.
  • Its Payables has fluctuated over the past 5 years, first plummeted by 33.50% in 2022, then surged by 155.17% in 2024.
  • Tg Therapeutics' Payables (Quarterly) stood at $51.3 million in 2021, then decreased by 18.08% to $42.0 million in 2022, then fell by 8.44% to $38.5 million in 2023, then skyrocketed by 51.53% to $58.3 million in 2024, then grew by 10.78% to $112.3 million in 2025.
  • Its last three reported values are $112.3 million in Q3 2025, $134.0 million for Q2 2025, and $133.9 million during Q1 2025.